Jefferies raised the firm’s price target on Cibus (CBUS) to $3 from $1.90 and keeps a Hold rating on the shares. With the capital raise in January and cost cutting measures, Cibus aims tot have ample cash for operating expenses and capex through at least 3Q26, the analyst tells investors in a research note. With EU genetic engineering regulations likely finalized in Q2, the firm expects a pickup in customer engagement in trait insertion, single-cell cloning, field trial efficiency solutions, and biofragrance production.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBUS:
- Cibus, Inc. Earnings Call Signals Promise Amid Pressure
- Morning Movers: Macy’s rises, General Mills slips after quarterly earnings
- Closing Bell Movers: Lululemon slips after earnings
- Cibus reports Q4 EPS (59c) vs. (87c) last year
- Cibus Global Inc options imply 19.8% move in share price post-earnings
